The AI Biotech Fund is a wholesale only innovative investment vehicle focused on generating significant capital appreciation by leveraging advanced AI-driven strategies. The fund aims to invest in biotech and pharmaceutical stocks that are undergoing clinical trials with near-term readouts that are expected to lead to significant movements in share prices.
Key to the fund’s strategy is the use of TrialKey, an AI/machine learning model developed by Opyl (ASX: OPL), which predicts the likelihood of clinical trial success. By integrating TrialKey’s predictive capabilities with other quantitative and qualitative data, the fund will develop a robust trading model to identify and capitalise on investment opportunities within the biotech and pharmaceutical sectors.
If you're interested in learning mor about the fund please fill in the form below.